Highlights Vivos Therapeutics, Inc.

Equities

VVOS

US92859E2072

Real-time Estimate Cboe BZX Other stock markets 11:34:48 2024-04-30 am EDT			5-day change	1st Jan Change
2.44 ^USD	-5.79%		-7.17%	-80.23%

Apr. 01	Signs of Softening Inflation Fuel Narrow Premarket Gains for US Equity Futures	MT
Apr. 01	Top Premarket Decliners	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Signs of Softening Inflation Fuel Narrow Premarket Gains for US Equity Futures	Apr. 01	MT
Top Premarket Decliners	Apr. 01	MT
Vivos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Earnings Flash (VVOS) VIVOS THERAPEUTICS Posts Q4 Revenue $3.2M	Mar. 28	MT
Vivos Therapeutics, Inc. Receives FDA Clearance to Vivos Care Oral Appliances to Treat Severe OSA in Adults	Feb. 06	CI
Vivos Therapeutics, Inc. Sees Positive Preliminary Metrics Following Unprecedented FDA 510(k) Clearance of the Company's Proprietary Oral Medical Devices to Treat Severe OSA	Jan. 08	CI
Vivos Therapeutics Receives FDA 510(k) Clearance for Oral Device Treatment for Sleep Apnea; Shares Soar	Nov. 29	MT
Vivos Therapeutics, Inc. Receives First Ever FDA 510(k) Clearance for Oral Device Treatment of Severe Obstructive Sleep Apnea	Nov. 29	CI
Vivos Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Earnings Flash (VVOS) VIVOS THERAPEUTICS Reports Q3 Revenue $3.3M, vs. Street Est of $4.14M	Nov. 14	MT
Vivos Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-16	CI
Earnings Flash (VVOS) VIVOS THERAPEUTICS Reports Q2 Revenue $3.4M, vs. Street Est of $4.1M	23-08-16	MT
Vivos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-06-08	CI
Earnings Flash (VVOS) VIVOS THERAPEUTICS Reports Q1 Revenue $3.9M, vs. Street Est of $4.01M	23-06-08	MT
Vivos Therapeutics, Inc. Announces Clinical Study Shows 92% of Patients Report Resolution of Migraine Headaches Using Vivos’ Po Appliance Treatment	23-05-01	CI
Vivos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
Earnings Flash (VVOS) VIVOS THERAPEUTICS Posts Q4 Revenue $4M	23-03-30	MT
Vivos Therapeutics Regains Nasdaq Listing Compliance	23-01-20	MT
Vivos Therapeutics Obtains FDA Approval for Device to Treat Sleep Apnea; Shares Surge Pre-Bell	23-01-04	MT
Vivos Therapeutics, Inc. Receives FDA 510(k) Clearance of its DNA Oral Appliance for Treatment of Obstructive Sleep Apnea	23-01-04	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Vivos Therapeutics, Inc.

Equities

VVOS

US92859E2072

Highlights

Filters